200 related articles for article (PubMed ID: 22869579)
1. Nevirapine exposure with WHO pediatric weight band dosing: enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience.
Nikanjam M; Kabamba D; Cressey TR; Burger D; Aweeka FT; Acosta EP; Spector SA; Capparelli EV
Antimicrob Agents Chemother; 2012 Oct; 56(10):5374-80. PubMed ID: 22869579
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Nevirapine Prophylactic and Therapeutic Dosing Regimens for Neonates.
Cressey TR; Punyawudho B; Le Coeur S; Jourdain G; Saenjum C; Capparelli EV; Jittayanun K; Phanomcheong S; Luvira A; Borkird T; Puangsombat A; Aarons L; Sukrakanchana PO; Urien S; Lallemant M;
J Acquir Immune Defic Syndr; 2017 Aug; 75(5):554-560. PubMed ID: 28489732
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian children.
Corbett AH; Hosseinipour MC; Nyirenda J; Kanyama C; Rezk NL; Mkupani P; Sichali D; Tien H; Kashuba AD; Mwansambo C; Weigel R; Kazembe P
Antivir Ther; 2010; 15(1):83-90. PubMed ID: 20167994
[TBL] [Abstract][Full Text] [Related]
4. Steady-state nevirapine, lamivudine and stavudine levels in Malawian HIV-infected children on antiretroviral therapy using split Triomune 30 tablets.
Poerksen G; Pollock L; Moons P; Chesshyre E; Burger D; Khoo S; Molyneux E
Antivir Ther; 2010; 15(3):343-50. PubMed ID: 20516554
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children.
Chokephaibulkit K; Cressey TR; Capparelli E; Sirisanthana V; Muresan P; Hongsiriwon S; Ngampiyaskul C; Limwongse C; Wittawatmongkol O; Aurpibul L; Kabat B; Toye M; Smith ME; Eksaengsri A; McIntosh K; Yogev R;
Antivir Ther; 2011; 16(8):1287-95. PubMed ID: 22155910
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of nevirapine dosing recommendations in HIV-infected children.
Foissac F; Bouazza N; Frange P; Blanche S; Faye A; Lachassinne E; Dollfus C; Hirt D; Benaboud S; Treluyer JM; Urien S
Br J Clin Pharmacol; 2013 Jul; 76(1):137-44. PubMed ID: 23278548
[TBL] [Abstract][Full Text] [Related]
7. Developmental pharmacokinetic changes of Lamivudine in infants and children.
Tremoulet AH; Nikanjam M; Cressey TR; Chokephaibulkit K; McKinney R; Mirochnick M; Capparelli EV
J Clin Pharmacol; 2012 Dec; 52(12):1824-32. PubMed ID: 22180560
[TBL] [Abstract][Full Text] [Related]
8. Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly in breast-feeding infants from birth to 6 months.
Shetty AK; Coovadia HM; Mirochnick MM; Maldonado Y; Mofenson LM; Eshleman SH; Fleming T; Emel L; George K; Katzenstein DA; Wells J; Maponga CC; Mwatha A; Jones SA; Abdool Karim SS; Bassett MT;
J Acquir Immune Defic Syndr; 2003 Dec; 34(5):482-90. PubMed ID: 14657758
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetic predictors of nevirapine pharmacokinetics in Ghanaian children living with HIV with or without TB coinfection.
Langaee T; Al-Shaer MH; Gong Y; Lima E; Antwi S; Enimil A; Dompreh A; Yang H; Alghamdi WA; Wiesner L; Peloquin CA; Kwara A
Infect Genet Evol; 2021 Aug; 92():104856. PubMed ID: 33839311
[TBL] [Abstract][Full Text] [Related]
10. A chewable pediatric fixed-dose combination tablet of stavudine, lamivudine, and nevirapine: pharmacokinetics and safety compared with the individual liquid formulations in human immunodeficiency virus-infected children in Thailand.
Vanprapar N; Cressey TR; Chokephaibulkit K; Muresan P; Plipat N; Sirisanthana V; Prasitsuebsai W; Hongsiriwan S; Chotpitayasunondh T; Eksaengsri A; Toye M; Smith ME; McIntosh K; Capparelli E; Yogev R;
Pediatr Infect Dis J; 2010 Oct; 29(10):940-4. PubMed ID: 20453709
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403.
King JR; Nachman S; Yogev R; Hodge J; Aldrovandi G; Hughes MD; Chen J; Wiznia A; Damle B; Acosta EP
Pediatr Infect Dis J; 2005 Oct; 24(10):880-5. PubMed ID: 16220085
[TBL] [Abstract][Full Text] [Related]
12. Bioavailability of extended-release nevirapine 400 and 300 mg in HIV-1: a multicenter, open-label study.
Battegay M; Arasteh K; Plettenberg A; Bogner JR; Livrozet JM; Witt MD; Mossdorf E; Yong CL; Zhang W; Macha S; Berger F; Stern J; Robinson P; Quinson AM
Clin Ther; 2011 Sep; 33(9):1308-20. PubMed ID: 21872931
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine.
Chokephaibulkit K; Plipat N; Cressey TR; Frederix K; Phongsamart W; Capparelli E; Kolladarungkri T; Vanprapar N
AIDS; 2005 Sep; 19(14):1495-9. PubMed ID: 16135903
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.
Lapphra K; Vanprapar N; Chearskul S; Phongsamart W; Chearskul P; Prasitsuebsai W; Chokephaibulkit K
Int J Infect Dis; 2008 Nov; 12(6):e33-8. PubMed ID: 18573672
[TBL] [Abstract][Full Text] [Related]
15. Nevirapine plasma concentrations in premature infants exposed to single-dose nevirapine for prevention of mother-to-child transmission of HIV-1.
Mugabo P; Els I; Smith J; Rabie H; Smith P; Mirochnick M; Steyn W; Hall D; Madsen R; Cotton MF
S Afr Med J; 2011 Sep; 101(9):655-8. PubMed ID: 21920159
[TBL] [Abstract][Full Text] [Related]
16. Nevirapine extended-release for the treatment of HIV-1 infection.
Bogner JR
Expert Rev Anti Infect Ther; 2012 Jan; 10(1):21-30. PubMed ID: 22149611
[TBL] [Abstract][Full Text] [Related]
17. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
Mbuagbaw L; Mursleen S; Irlam JH; Spaulding AB; Rutherford GW; Siegfried N
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD004246. PubMed ID: 27943261
[TBL] [Abstract][Full Text] [Related]
18. Dosage optimization of treatments using population pharmacokinetic modeling and simulation.
Guidi M; Arab-Alameddine M; Rotger M; Aouri M; Telenti A; Decosterd LA; Buclin T; Csajka C;
Chimia (Aarau); 2012; 66(5):291-5. PubMed ID: 22867538
[TBL] [Abstract][Full Text] [Related]
19. Nevirapine Pharmacokinetics and Safety in Neonates Receiving Combination Antiretroviral Therapy for Prevention of Vertical HIV Transmission.
Lau E; Brophy J; Samson L; Kakkar F; Campbell DM; Yudin MH; Murphy K; Seto W; Colantonio D; Read SE; Bitnun A
J Acquir Immune Defic Syndr; 2017 Apr; 74(5):493-498. PubMed ID: 28114187
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics-based adherence measures for antiretroviral therapy in HIV-infected Kenyan children.
Tu W; Nyandiko WM; Liu H; Slaven JE; Scanlon ML; Ayaya SO; Vreeman RC
J Int AIDS Soc; 2017 Jun; 20(1):21157. PubMed ID: 28605170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
